Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket: retatrutide, tirzepatide | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 10 Parkinson's papers of 741 | 0.69 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 6307
Sealed predictions
- GIPR in dopamine neurons, braak-0.11 (p 0.787) → -0.13 (p 0.735)receipt 6315
Swarm cases
receipt 6315: GIPR in dopamine neurons, braak
- power
- full sample -0.12 (p 0.633, n 18), 95% CI -0.56 to +0.37. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.11 (p 0.652, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.10 (p 0.696, n 18). could be the mix.
- skeptic
- leave-one-out range -0.28 to -0.01, sign flips 0; without severely affected donors -0.12 (p 0.633, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for GIPR in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts